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Abstract
Background: Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors
or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine
tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice.
Methods: This retrospective cross-sectional analysis of patients with NETs treated with the SSA lanreotide and targeted
therapies at 35 Spanish hospitals evaluated the efficacy and safety of lanreotide treatment combinations in clinical
practice. The data of 159 treatment combinations with lanreotide in 133 patients was retrospectively collected.
Results: Of the 133 patients, with a median age of 59.4 (16–83) years, 70 (52.6 %) patients were male, 64 (48.1 %)
had pancreatic NET, 23 (17.3 %) had ECOG PS ≥2, 41 (30.8 %) had functioning tumours, 63 (47.7 %) underwent surgery
of the primary tumour, 45 (33.8 %) had received prior chemotherapy, and 115 (86.5 %) had received prior SSAs.
115 patients received 1 lanreotide treatment combination and 18 patients received between 2 and 5 combinations.
Lanreotide was mainly administered in combination with everolimus (73 combinations) or sunitinib (61 combinations).
The probability of being progression-free was 78.5 % (6 months), 68.6 % (12 months) and 57.0 % (18 months) for
patients who only received everolimus plus lanreotide (n = 57) and 89.3 % (6 months), 73.0 % (12 months), and 67.4 %
(18 months) for patients who only received sunitinib and lanreotide (n = 50). In patients who only received everolimus
plus lanreotide the median time-to-progression from the initiation of lanreotide combination treatment was
25.8 months (95 % CI, 11.3, 40.3) and it had not yet been reached among the subgroup of patients only receiving
sunitinib plus lanreotide. The safety profile of the combination treatment was comparable to that of the targeted
agent alone.
Conclusions: The combination of lanreotide and targeted therapies, mainly everolimus and sunitinib, is widely
used in clinical practice without unexpected toxicities and suggests efficacy that should be explored in
randomized prospective clinical trials.
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Background
Neuroendocrine tumours (NETs) are a heterogeneous
group of relatively rare malignancies originating from the
diffuse neuroendocrine system found most often in the
bronchial or gastrointestinal systems [1]. Somatostatin
analogues (SSAs) are a key therapeutic option in the
management of advanced NETs, leading to a significant
improvement in patient quality of life [2–5]. There are
currently 2 SSAs in clinical use: octreotide [6] and lanreo-
tide [7, 8]. Longer acting (slow-release and depot) formu-
lations of SSAs include octreotide long-acting release
(LAR), lanreotide Autogel and lanreotide LP. Small studies
have suggested that treatment with SSAs is associated with
disease stabilization and prolonged progression-free sur-
vival (PFS) in some patients with NETs [8, 9]. Moreover,
following the randomized PROMID study confirming that
octreotide delayed time to tumour progression (TTP)
(from 6 to 14.3 months, hazard ratio [HR] = 0.34; p ≤
0.0001) in patients with metastatic NETs [9], SSAs have
been administered to patients to provide not only hormo-
nal symptom control but also antitumour activity [10].
A Phase II trial carried out by the Spanish TTD group
evaluated the efficacy of lanreotide Autogel 120 mg on
tumour growth stabilization in 30 patients with progres-
sive gastroenteropancreatic and bronchopulmonary NETs.
The median PFS was 12.9 months with clinical benefit
reported in 93 % of the patients [11]. In the international
Phase III Clarinet trial lanreotide substantially prolonged
PFS compared with placebo (HR = 0.47; 95 % CI 0.30–
0.73; p < 0.001) in patients with non-functioning gastro-
enteropancreatic NETs [12].
Recent therapeutic advances with everolimus, a mam-
malian target of rapamycin (mTOR) inhibitor, and suniti-
nib, a multitargeted agent with antiangiogenic activity,
have led to an improvement in patients with advanced
pancreatic NETs (pNETs) [13–16]. Everolimus has shown
antitumour activity in 2 Phase III studies (RADIANT-2
and RADIANT-3). In RADIANT-2, treatment with eve-
rolimus plus octreotide resulted in a 5.1-month increase
in median PFS compared with placebo plus octreotide
(16.4 vs. 11.3 months) in patients with advanced NETs
with carcinoid syndrome, although the difference did not
reach statistical significance [13]. In RADIANT-3, patients
with progressive pNETs had a statistically significant im-
provement in PFS associated with everolimus compared
with placebo (11 vs. 4.6 months). A Phase III study of
sunitinib in patients with progressive pNETs was un-
blinded early after more than a doubling of median PFS
(11.4 vs. 5.5 months) favoured the patients receiving
sunitinib vs. placebo [14]. After a 2-year follow-up, the
median overall survival (OS) was estimated at 33 months
in the sunitinib arm [17].
The combination of SSAs and targeted therapies is a
potential treatment option for patients with NETs [18].
Indeed, several small studies suggest that the combined
use of octreotide and everolimus could provide an in-
crease in efficacy [13, 19, 20]. Unfortunately, no random-
ized data have compared the outcome of patients who
received a novel targeted agent alone vs. the combination
with a SSA. However, in clinical practice, targeted therap-
ies are frequently combined with SSAs and there have
been reports of valuable efficacy in heavily pretreated
patients [21]; thus in a retrospective cohort, 83 % of 29
patients with well differentiated pNETs who were treated
with sunitinib in daily practice in Spain also received
concomitant treatment with SSAs [22]. Furthermore,
Barriuso et al., reported that 87.5 % of 40 patients with
NETs on treatment with sunitinib as palliative treatment
in 6 Spanish hospitals, concomitantly received SSAs [23].
The aim of this retrospective cross-sectional analysis
was to define the efficacy and safety of the SSA, lanreotide,
in combination with antiangiogenic targeted therapies or
inhibitors of the mTOR pathway in the routine clinical
practice, to help evaluate their potential clinical benefit in
the management of patients with NETs in Spain.
Methods
Design
Between July 2011 and October 2011 we collected the
data from patient medical charts to perform a retro-
spective multicentre cross-sectional analysis of patients
with NETs that were treated with the SSA lanreotide
combined with novel targeted therapies. Data were col-
lected from medical oncology services of Spanish hospi-
tals with experience in the treatment of NETs with
lanreotide and newer therapeutic agents, such as mTOR
inhibitors or antiangiogenic agents (tyrosine kinase in-
hibitors [TKIs] or monoclonal antibodies). Thirty-five
centres distributed over 27 Spanish provinces were
identified and invited to participate in the project. The
conduct of this retrospective cross-sectional analysis was
approved by the ethics committee of the Vall d’Hebron
University Hospital.
Objectives
We wanted to determine the epidemiologic characteris-
tics of the patients analysed, in terms of proliferative rate
and location of the primary tumour, functionality, differ-
entiation and tumour extension, as well as treatments
received prior to the combination therapy. The main
efficacy objectives included determining the drugs used
in the course of the combined therapy, the length of this
combination therapy, biochemical response (50 % reduc-
tion of chromogranin A), the radiologic response rate
obtained according to Response Evaluation Criteria In
Solid Tumours (RECIST) v1.0, and response duration.
The radiologic images were not centrally reviewed by
the investigators; the information on progression was
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Table 1 Patient demographics, disease characteristics, and prior
treatment regimens
Characteristic Number of patients
(N = 133)
Sex, n (%)
Male 70 (52.6)
Female 63 (47.4)
Age, years
Median (range) 59.4 (16–83)
Comorbidities, n (%)
Hypertension 51 (38.3)
Diabetes 37 (27.8)
Dyslipidaemia 25 (18.8)
Heart disease 19 (14.3)
Liver disease 6 (4.5)
Hypothyroidism 12 (9.0)
Tumour extension at diagnosis, n (%)
Locally advanced 6 (4.5)
Metastatic 127 (95.5)
Tumour extension at treatment initiation, n (%)
Locally advanced 2 (1.5)
Metastatic 131 (98.5)
ECOG PS, n (%)
0 45 (33.8)
1 65 (48.9)
2 22 (16.5)
3 1 (0.8)
Location of primary tumour, n (%)
Foregut 85 (64.0)
Lung 12 (9.0)
Oesophagus 1 (0.8)
Stomach 3 (2.3)
Duodenum 5 (3.8)
Pancreas 64 (48.1)
Midgut 30 (22.6)
Jejunum 3 (2.3)
Ileum 21 (15.8)
Appendix 2 (1.5)
Cecum 4 (3.0)
Hindgut 6 (4.5)
Colon 3 (2.3)
Rectum 3 (2.3)
Unknown 12 (9.0)
Histological differentiation, n (%)
Grade 1 55 (41.4)
Grade 2 42 (31.6)
Table 1 Patient demographics, disease characteristics, and prior
treatment regimens (Continued)
Grade 3 2 (1.5)
Unknown 34 (25.6)
Location of metastases, n (%)
Liver 112 (84.2)
Bone 18 (13.5)
Peritoneum 19 (14.3)
Lung 19 (14.3)
Lymph node 29 (21.8)
Othera 4 (3.0)
Tumour functionality, n (%)
Non-functioning 92 (69.2)
Functioning 41 (30.8)
Carcinoid 13 (9.8)
Gastrinoma 1 (0.8)
Somatostinoma 1 (0.8)
VIPoma 3 (2.3)
Not specified 23 (17.3)
Ki-67 index, n (%)
0–2 52 (39.1)
3–10 29 (21.8)
11–20 8 (6.0)
> 20 1 (0.8)
Unknown 43 (32.3)
Previous non-pharmacologic treatments, n (%)
Surgery of the primary tumour 63 (47.4 %)
Surgery of metastases 21 (15.8 %)
Local treatmentsb 23 (17.3)
Radiotherapy 6 (4.5)
Previous pharmacologic treatments, n (%)
None 16 (12.0)
Chemotherapy 45 (33.8)
Targeted therapy 16 (12.0)
Immunotherapy 7 (5.3)
Somatostatin analogues
Lanreotide 78 (58.6)
Octreotide 37 (27.8)
Combination with somatostatin analogues
Interferon 19 (14.3)
Targeted therapy 7 (5.3)
aOther metastatic sites include breast (n = 1), pleura (n = 1), spleen (n = 1),
adrenal gland (n = 1)
bIncludes embolization, (transarterial) chemoembolization, radiofrequency
ablation and radioembolization
ECOG PS, Eastern Cooperative Group Oncology Performance Status; VIPoma,
Vasoactive intestinal peptide secreting tumour
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obtained from the patients’ medical chart. TTP was de-
fined as the time from the initiation of lanreotide combin-
ation therapy until there was an indication of disease
progression as noted in the patients’ clinical history. In line
with the retrospective nature of this analysis, it is import-
ant to point out that the progression status had no plan-
ning dates for the estimation of TPP. OS was defined from
the initiation of lanreotide combination therapy until pa-
tient death. Safety objectives were to collect the reasons
for discontinuing the combined therapy, and to define the
adverse events (AEs) profile according to the Common
Terminology Criteria for Adverse Events (CTCAE) v3.0.
Patient population
All patients diagnosed with NET being followed at the
medical oncology services who had received treatment with
lanreotide in combination with a novel therapeutic target
agent for at least 3 months prior to data collection into an
electronic Data Report Form were eligible to be included in
the retrospective analysis. All patients had progressed on
previous treatment before receiving combination treatment
with lanreotide. If the length of combination treatment did
not reach 3 months, the patient would still be eligible for
inclusion as long as treatment discontinuation was due to
an AE. The 3-month minimum combined treatment
cut-off would be used to exclude patients who abandoned
combination treatment very early; however, there were pa-
tients included in the analysis who received combined treat-
ment for less than 3 months. Upon progression with the
lanreotide combination, patients received further treatment
according to the standard of care at each centre.
Statistical analysis
Summary statistics are presented for all variables. Efficacy
was assessed on the basis of tumour response. Kaplan-Meier
methods were used to obtain estimates of median TTP and
OS, with corresponding HRs and 2-sided 95 % confidence
intervals (CIs). The protocol was approved by the Ethics
Committee of the hospitals where data was collected.
Results
Patient population
One hundred and thirty-three patients with a diagnosis of
NET who received combination treatment with lanreotide
and targeted therapy in the setting of routine clinical prac-
tice were analysed. Patients began receiving lanreotide
combination treatment between April 2008 and July 2011.
The demographic and clinical characteristics of the pa-
tients are described in Table 1. The median age of patients
with NETs was 59.4 years, and their main comorbidities
were hypertension and diabetes. Approximately half of the
patients had pNETs; the primary site was the ileum in 21
(15.8 %) patients and the lung in 12 (9.0 %) patients. Almost
all patients had metastatic disease at diagnosis (98.5 %) and
the liver was the most common metastatic location (84.2 %).
Thirty-one percent of patients had functional tumours
(carcinoid, gastrinoma, somatostinoma and vasoactive intes-
tinal peptide secreting tumour [VIP]oma). The majority of
patients had received prior pharmacologic treatment. The
number of prior treatment lines was 1 for 52 (39.1 %)
patients, 2 for 31 (23.3 %) patients, 3 for 19 (14.3 %)
patients, 4 for 9 (6.8 %) patients, and 5 for 6 (4.5 %) patients.
Treatment and patient disposition
According to the investigators’ criteria, the main reason
for combining lanreotide with targeted therapies was to
achieve antiproliferative synergy (113 patients, 85.0 %). In
the other patients, the main reason was to control hormo-
nal symptoms. The majority (115 patients, 86.5 %) of pa-
tients received only 1 lanreotide treatment combination;
but, overall, the 133 patients included in the analysis
received a total of 159 combinations of targeted therapy
with lanreotide (Table 2) so there were patients that
Table 2 Treatment combinations in the 133 patients analysed
Number of patients
(N = 133)
Number of treatment combinations, n (%)
1 115 (86.0)
2 12 (9.0)
3 5 (3.8)
5 1 (0.8)
Number of treatment
combinations
(N = 159)
Targeted agent combined with lanreotide, n (%)
Everolimus 73 (45.9)
Sunitinib 61 (38.4)
Treatment discontinuation, n (%)a 84 (52.8)
Everolimus n = 73
All discontinuations 39 (53.4)
Disease progression 23 (31.5)
Adverse event 10 (13.7)
Other 6 (8.2)
Ongoing 34 (46.6)
Sunitinib n = 61
All discontinuations 27 (44.3)
Disease progression 15 (24.6)
Adverse event 10 (16.4)
Other 2 (3.3)
Ongoing 34 (55.7)
aThe denominator is the number of treatment combinations with a each targeted
agent
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received 2 or more combinations. As expected, the most
common combinations were with everolimus (73 combi-
nations, 45.9 % of the 159 combinations) and sunitinib
(61 combinations, 38.4 % of the 159 combinations). Other
combinations with targeted agents included bevacizumab
(n = 9), sorafenib (n = 8), and pazopanib (n = 8); however,
due to the small number of patients that received each of
these combinations individual characterization of the
outcomes of these combinations was not carried out. With
a median follow-up of 43.9 months (range 1.8–628.7), the
median duration of treatment was 5.1 months (range
0–35.6) in the 115 patients who only received 1 treatment
combination. In the 57 patients who only received everoli-
mus plus lanreotide the median follow-up was 42.2 months
(range 1.8–275.1) and the median duration of treatment
was 4.7 months (range 0–35.6). Similarly, in the 50
patients who only received the combination of sunitinib
with lanreotide, the median follow-up was 31.8 months
(range 2.8–628.7), with a median duration of treatment of
5.9 months (range 0.4-25.0). There were 4 patients receiv-
ing everolimus plus lanreotide (range 0.59–2.95 months)
and 2 patients receiving sunitinib plus lanreotide (range
0.39–2.98 months) that received treatment for less than
3 months and discontinued due to an AE. In addition
there were 5 patients receiving the everolimus and lanreo-
tide combination for less than 3 months that discontinued
due to tumour progression (range 0–2.98 months).
In 128 of the 159 combinations the dose of lanreotide
Autogel was 120 mg every 28 days. Everolimus was admin-
istered at a dose of 10 mg/day in 72 combinations and at
5 mg/day in 1 combination. The administration of sunitinib
was less homogeneous, 49 combinations with a continuous
dose of 37.5 mg/day, 11 combinations of 50 mg/day suniti-
nib on a 4 weeks on/2 weeks off schedule, and 1 patient
who received 25 mg/day.
At the time of the data cut-off, 84 treatment combina-
tions (52.8 % of 159) had been discontinued. The
reasons for treatment discontinuation were disease pro-
gression in 47 (29.6 % of 159) combinations and AEs in
24 (15.1 % of 159) combinations (Table 2).
Data on follow-up treatment was collected for 30 pa-
tients. Fourteen patients received a SSA, either as mo-
notherapy or in combination with another agent. Five
patients received sunitinib, either as monotherapy or in
combination with a SSA and four patients received everoli-
mus, either as monotherapy or in combination with lanreo-
tide. Eight patients received chemotherapy combinations.
Efficacy
Overall, 23 treatment combinations led to a tumour
response (1 complete response [CR] and 22 partial
responses [PRs]) resulting in an objective response rate of
14.5 % with all treatment combinations (Table 3). Stable
disease (SD) was reported in 113 (71.1 %) treatment
combinations and the disease control rate was 85.5 %. The
response (18.3 %; with 1 CR and 20 PRs) and disease
control rates (82.6 %) were similar in the subgroup of the
115 patients who only received 1 treatment combination.
Chromogranin A expression was measured in 37 (27.8 %)
patients, with normalization reported in 6 (16.2 % of 37)
patients and a reduction in 10 (27.0 % of 37) patients.
A correlation between chromogranin A expression and
Table 3 Radiologic response rate in all 133 patients (analysed all 159 treatment combinations) and in the 115 patients that only
received one lanreotide combination
All patients All treatment combinations Everolimus + lanreotide Sunitinib + lanreotide
N = 159a n = 73 n = 61
Tumour response (%)
Complete response 1 (0.6) 0 1 (1.6)
Partial response 22 (13.8) 11 (15.1) 9 (14.8)
Stable disease 113 (71.1) 49 (67.0) 42 (68.9)
Progressive disease 13 (8.2) 9 (12.3) 3 (4.9)
Not evaluated 10 (6.2) 4 (5.5) 6 (9.8)
Patients that received only one lanreotide combination One treatment combination
n = 115 n = 57 n = 50
Tumour response (%)
Complete response 1 (0.9) 0 1 (2.0)
Partial response 20 (17.4) 10 (17.5) 8 (16)
Stable disease 74 (64.3) 35 (61.5) 34 (68.0)
Progressive disease 11 (9.6) 8 (14.0) 2 (4.0)
Not evaluated 9 (7.8) 4 (7.0) 5 (10)
aThe denominator is the total number of treatment combinations in 133 patients analysed
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radiologic tumour response was not carried out because
many chromogranin A measurements were missing. One
third of the patients did not have Ki67 data and prolifera-
tion index was not analysed.
Subanalysis of patients that only received everolimus and
lanreotide or sunitinib and lanreotide
Among the 115 patients who received only 1 lanreotide
treatment combination, 57 patients received everolimus
Fig. 1 Time to progression. Kaplan-Meier curves indicating the time to progression in all patients receiving only everolimus + lanreotide (n = 56)*
or sunitinib + lanreotide (n = 50), in patients with pNETs receiving everolimus + lanreotide (n = 26)* or sunitinib + lanreotide (n = 28), and in
patients with extrapancreatic neuroendocrine tumours receiving everolimus + lanreotide (n = 30) or sunitinib + lanreotide (n = 22). *Information on
tumour progression was missing in 1 patient receiving everolimus + lanreotide
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plus lanreotide and 50 patients received sunitinib plus lan-
reotide. In patients who only received everolimus plus lan-
reotide the median TTP from the initiation of combination
treatment was 25.8 months (95 % CI, 11.3, 40.3) and it had
not yet been reached among the subgroup of patients
receiving sunitinib and lanreotide (Fig. 1). The probability of
being progression-free at 6 months was 78.5 % in the evero-
limus and lanreotide group and 89.3 % in the sunitinib and
lanreotide group and at 12 months it was 68.6 and 73.0 %,
in the everolimus and sunitinib patient groups, respectively.
At 18 months, 57.0 % of patients receiving everolimus plus
lanreotide and 67.4 % of patients receiving sunitinib plus
lanreotide were estimated to be free of progression. The
median OS was 26.4 months (95 % CI, 17.5, 35.4) for
patients receiving everolimus and lanreotide and 32.8months
(95 % CI, 12.5, 53.0) for sunitinib subgroup (Fig. 2).
Fig. 2 Overall survival. Overall survival Kaplan-Meier curves in all patients receiving only everolimus + lanreotide (n = 57) or sunitinib + lanreotide
(n = 50), in patients with pNETs receiving everolimus + lanreotide (n = 27) or sunitinib + lanreotide (n = 28), and in patients with extrapancreatic
neuroendocrine tumours receiving everolimus + lanreotide (n = 30) or sunitinib + lanreotide (n = 22)
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Safety
Overall there were 270 AEs in 97 patients (Table 4).
The majority of AEs reported were Grade 1 (n = 115)
or 2 (n = 106) in severity, with few Grade 3 (n = 39)
or Grade 4 (n = 9) AEs. Generally, the safety profile
of the combination with lanreotide resembled the
safety profile of the targeted agent in monotherapy
(Table 5). The main AEs were asthenia, mucositis,
and diarrhoea. There were 6 AEs (5 AEs were Grade
1 or 2) that were related to lanreotide administration;
these included diarrhoea, hyperglycaemia, and abdominal
pain.
At the data cut-off, 3 patients were alive without dis-
ease, 106 patients were alive with disease and there had
been 24 deaths (22 due to disease progression, 1 cardiac
insufficiency and 1 death in a patient receiving everoli-
mus plus lanreotide that was not due to disease progres-
sion and was potentially considered by the investigator
to be a Grade 5 AE).
Discussion
This cross-sectional analysis retrospectively evaluated the
clinical use of the SSA lanreotide in combination with
targeted agents in Spanish patients with advanced NETs in
the setting of routine clinical practice. As expected, in
the majority of patients, lanreotide was administered
with everolimus or sunitinib. The probability of being
progression-free was encouraging in the patient population
analysed (patients who survived or maintained treatment
for more than 3 months). The estimated proportion of pa-
tients who were alive and progression-free at 18 months
was 34 % with everolimus in the RADIANT-3 trial [15] and
in the sunitinib Phase 3 trial it was estimated that 71.3 % of
patients were alive and progression-free at 6 months [14].
In the RADIANT-3 trial there were 40 % of patients that
received concomitant treatment with SSAs, but median
PFS for treatment with everolimus was similar in the
group of patients that received SSAs (11.4 months) and in
the group of patients that did not (10.8 months) [24]. In
the Phase II RADIANT-1 study, the median PFS by
central radiology review was 16.7 months and the median
OS had not been reached at the time of data cut-off in the
subgroup of patients who received everolimus plus octreo-
tide [19]. In the subgroup of patients receiving everoli-
mus monotherapy median PFS was 9.7 months and
median OS was 24.9 months. A subanalysis of the 40 %
of patients receiving SSAs in the Phase III sunitinib
study showed that their use resulted in a nonstatisti-
cally significant improvement in PFS (HR 0.78; p = 0.31)
compared with the patients who received no on-study
SSA [25].
In our cross-sectional analysis there might appear to
be differences in the efficacy results between everolimus
or sunitinib; however, this analysis was not set up to
compare the data between the different targeted agents
that are routinely combined with lanreotide in clinical
practice and therefore it should not be assumed that one
of the targeted agents analysed here would be a better
combination partner for lanreotide. There are several
limitations that should be taken into account when dis-
secting the data in our cohort of patients. This is a
cross-sectional and retrospective analysis of patients be-
ing treated at selected sites that are presumed to be ref-
erence sites for the treatment of NETs and to have
experience in the management of novel targeted agents.
Furthermore, there was a bias in the selection process
since the patients included in this retrospective analysis
should have been receiving treatment for at least
3 months except for those who did not tolerate the com-
bination. This inherent selection bias probably underes-
timates the number of patients in clinical practice with
early progression with the combination strategy. There
were no strict timelines to assess tumour response, no
central review of the images, and patient follow up was
Table 4 Treatment-related AEs in all patients; N = 133
All AEs Grade≥ 3
n (%) n (%)
Asthenia 48 (36.1) 13 (9.8)
Mucositis 35 (26.3) 6 (4.5)
Diarrhoea 33 (24.8) 4 (3.0)
Hand-foot skin reaction 20 (15.0) 1 (0.8)
Anorexia 16 (12.0) 2 (1.5)
Hyperglycaemia 13 (9.8) 1 (0.8)
Rash 12 (9.0) 3 (2.3)
Hypertension 12 (9.0) 1 (0.8)
Peripheral oedema 7 (5.3) 2 (1.5)
Thrombocytopenia 7 (5.3) 3 (2.3)
Anaemia 7 (5.3) 1 (0.8)
Pneumonitis 4 (3.0) 1 (0.8)
Cardiac toxicity 4 (3.0) 3 (2.3)
Hypercholesterolemia 4 (3.0) 0
Hypertriglyceridemia 4 (3.0) 0
Leucopoenia 4 (3.0) 1 (0.8)
Hepatic alterations 3 (2.3) 0
Hypothyroidism 3 (2.3) 0
Nausea 3 (2.3) 0
Vomiting 3 (2.3) 0
Abdominal pain 3 (2.3) 0
Weight loss 3 (2.3) 0
Headache 1 (0.8) 0
Epistaxis 1 (0.8) 0
Other 20 (15.0) 6 (4.5)
AE = adverse event
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performed according to local guidelines. In addition, the
sample of the analysis is very heterogeneous since there
are several patients who received subsequent lines of
treatment, including maintenance with lanreotide alone.
Furthermore, the dose of sunitinib that patients received
was heterogeneous; the majority of patients received
continuous daily dosing (the schedule that is approved
in Europe for patients with pNETs), but a considerable
share of patients followed the intermittent 4 weeks on
and 2 weeks off schedule that is the approved schedule
for advanced renal cell carcinoma (RCC) and gastro-
intestinal stromal tumour (GIST) [26]. In addition to
taking these limitations into account, it is important to
highlight that any potential clinical benefits should be con-
firmed in studies specifically designed to evaluate whether
combination therapy with a SSA is superior to the targeted
agent alone. Several trials are currently ongoing: SUN-
LAND (ClinicalTrials.gov NCT01731925) is a clinical trial
aimed at evaluating the activity of sunitinib, alone or in
combination with lanreotide, in midgut carcinoids. In
addition, a randomized phase II study, COOPERATE-2
(ClinicalTrials.gov NCT01374451), evaluating the treat-
ment effect of everolimus in combination with the SSA
pasireotide relative to everolimus alone on PFS in patients
with advanced progressive pNET, has completed accrual.
Furthermore, LUNA (ClinicalTrials.gov NCT01563354)
will test the effectiveness and safety of everolimus or pasir-
eotide alone or in combination in adult patients with
advanced neuroendocrine carcinoma (typical and atypical)
of the lung and thymus. The results from these studies are
eagerly awaited.
Combination of lanreotide with targeted therapies did
not lead to a significant increase in AEs when compared
with the safety profile of each targeted agent as mono-
therapy. Most common AEs of SSA treatment are usu-
ally mild, limited in time, and can include local reactions
Table 5 Number of adverse events (AEs) and Grade 3 or 4 AEs reported during the study and assignment of causality to the
treatment received. The number of Grade 3 and 4 AEs is shown in parenthesis
Everolimus Lanreotide and everolimus Sunitinib Lanreotide and sunitinib Lanreotide
All AEs (Grade 3–4) All AEs (Grade 3–4) All AEs (Grade 3–4) All AEs (Grade 3–4) All AEs (Grade 3–4)
AE 129 (21) 9 (2) 70 (17) 15 (5) 6 (1)
Asthenia 15 (5) 0 22 (8) 2 (0) 0
Mucositis 25 (6) 0 6 (0) 0 0
Diarrhoea 17 (2) 1 (0) 5 (1) 5 (1) 1 (0)
Hand-foot skin reaction 8 (0) 0 8 (1) 0 0
Anorexia 9 (1) 0 4 (1) 0 0
Hyperglycaemia 7 (0) 4 (1) 0 1 (0) 1 (0)
Rash 10 (2) 1 (1) 0 0 0
Hypertension 2 (0) 0 6 (1) 0 0
Peripheral oedema 6 (2) 0 1 (0) 0 0
Thrombocytopenia 0 0 4 (0) 3 (3) 0
Anaemia 5 (0) 0 0 2 (1) 0
Pneumonitis 3 (1) 0 1 (0) 0 0
Cardiac toxicity 0 0 3 (2) 0 0
Hypercholesterolemia 4 (0) 0 0 0 0
Hypertriglyceridemia 4 (0) 0 0 0 0
Leucopoenia 1 (0) 0 2 (1) 1 (0) 0
Hepatic alterations 0 2 (0) 0 0 0
Hypothyroidism 0 0 3 (0) 0 0
Nausea 1 (0) 0 0 0 0
Vomiting 1 (0) 0 1 (0) 0 0
Abdominal pain 1 (0) 0 0 0 2 (0)
Weight loss 1 (0) 0 0 1 (0) 0
Headache 0 0 0 0 0
Epistaxis 0 0 1 (0) 0 0
Other 9 (2) 1 (0) 3 (2) 0 2 (1)
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(pain and erythema) at the injection site, abdominal
cramps, nausea, flatulence, diarrhoea, steatorrhoea and a
risk of cholelithiasis, more common after long exposure
to the drug [2].
Conclusions
The combination of lanreotide and everolimus or suniti-
nib is widely used in routine clinical practice at Spanish
hospitals without unexpected toxicities. The median
TTP of the patients receiving the combined treatment
with lanreotide appears to be clinically relevant. Further-
more, the data suggest that the combination of lanreo-
tide and everolimus or sunitinib might provide tumour
control in the majority of patients with NETs receiving
treatment. The possibility of enhanced efficacy when
combining SSAs and targeted therapies, suggests that
this approach should be further explored in randomized
prospective clinical trials.
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